Logo Logo

Publications by Rothenberg-Thurley, M.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 12.

Journal article

Reiter, K.; Polzer, H.; Krupka, C.; Maiser, A.; Vick, B.; Rothenberg-Thurley, M.; Metzeler, K. H.; Doerfel, D.; Salih, H. R.; Jung, G.; Noessner, E.; Jeremias, I.; Hiddemann, W.; Leonhardt, H.; Spiekermann, K.; Subklewe, M.; Greif, P. A. (2018): Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia. In: Leukemia, Vol. 32, No. 2: pp. 313-322

Herold, Tobias; Jurinovic, V.; Metzeler, K. H.; Batcha, A. M. N.; Bamopoulos, S. A.; Rothenberg-Thurley, M.; Ksienzyk, B.; Hartmann, L.; Greif, P. A.; Phillippou-Massier, J.; Krebs, S.; Blum, H.; Amler, S.; Schneider, S.; Konstandin, N.; Sauerland, M. C.; Berdel, W. E.; Wörmann, B. J.; Subklewe, M.; Fiegl, M.; Bohlander, S. K.; Braess, J.; Hiddemann, W.; Mansmann, Ulrich; Spiekermann, K. (2017): Prediction of Primary Refractory Acute Myeloid Leukemia. In: Annals of Hematology, Vol. 96: S25-S25

Prassek, V. V.; Rothenberg-Thurley, M.; Sauerland, M. C.; Amler, S.; Görlich, D.; Herold, T.; Janke, H.; Schneider, S.; Subklewe, M.; Krug, U.; Faldum, A.; Berdel, W.; Wörmann, B.; Bräss, J.; Spiekermann, K.; Hiddemann, W.; Metzeler, K. (2017): AML patients aged >= 75 years enrolled into AMLCG trials: do genetic alterations impact clinical outcome in very old, intensively treated patients? In: Oncology Research and Treatment, Vol. 40: p. 29

Stosch, J. M.; Heumüller, A.; Bleul, S.; Niemöller, C.; Rothenberg-Thurley, M.; Renz, N.; Riba, J.; Szic, Szarc Vel K.; Pfeifer, D.; Zimmermann, S.; Duyster, J.; Lübbert, M.; Wehrle, J.; Metzeler, K. H.; Claus, R.; Becker, H. (2017): MDS progression to AML associates with acquisition of single driver mutations with consequent changes in clonal architecture and occurrence of multiple clones with mutations in identical genes. In: Oncology Research and Treatment, Vol. 40: p. 131

Stosch, J.; Heumüller, A.; Bleul, S.; Niemöller, C.; Rothenberg-Thurley, M.; Renz, N.; Riba, J.; Szic, K. Szarc Vel; Pfeifer, D.; Nieters, A.; Zimmermann, S.; Duyster, J.; Lübbert, M.; Wehrle, J.; Metzeler, K.; Claus, R.; Becker, H. (2017): Progression of Mds to Aml Features Gain of Single Driver Mutations with Consequent Changes in Clonal Composition and Occurrence of Multiple Clones with Mutations in Identical Genes. In: Haematologica, Vol. 102: pp. 259-260

Prassek, V.; Rothenberg-Thurley, M.; Sauerland, M. C.; Amler, S.; Görlich, D.; Herold, T.; Janke, H.; Schneider, S.; Subklewe, M.; Krug, U.; Faldum, A.; Berdel, W. E.; Wörmann, B.; Braess, J.; Hiddemann, W.; Spiekermann, K.; Metzeler, K. H. (2017): AML patients aged >= 75 years enrolled into AMLCG trials: do genetic alterations impact clinical outcome in very old, intensively treated patients? In: Haematologica, Vol. 102: pp. 209-210

Konstandin, N. P.; Pastore, F.; Dufour, A.; Metzeler, K. H.; Rothenberg-Thurley, M.; Herold, T.; Schneider, S.; Ksienzyk, B.; Tschuri, S.; Berdel, W. E.; Wörmann, B. J.; Sauerland, C.; Bräss, J.; Stefan, B. K.; Hiddemann, W.; Spiekermann, K. (2017): Genetic Characterization of a Large Group of CEBPA Mutated AML Patients and the Effect of TET2 and GATA2 Mutations on Outcome. In: Haematologica, Vol. 102: pp. 363-364

Prassek, V. V.; Rothenberg-Thurley, M.; Herold, T.; Amler, S.; Sauerland, M. C.; Goerlich, D.; Janke, H.; Schneider, S.; Subklewe, Marion; Krug, U.; Faldum, A.; Berdel, W. E.; Woermann, B.; Buechner, T.; Braess, J.; Hiddemann, W.; Spiekermann, K.; Metzeler, K. H. (2017): AML Patients Aged >= 75 Years Enrolled into AMLCG Trials: Do Gene Mutations Impact Clinical Outcome in Very Old, Intensively Treated Patients? In: Annals of Hematology, Vol. 96: S63-S63

Rothenberg-Thurley, M.; Amler, S.; Goerlich, D.; Sauerland, M. C.; Schneider, S.; Konstandin, N. P.; Batcha, A. M.; Ksienzyk, B.; Zellmeier, E.; Mansmann, Ulrich; Subklewe, Marion; Bohlander, S. K.; Faldum, A.; Hiddemann, W.; Spiekermann, K.; Braess, J.; Metzeler, Klaus H. (2017): Persistence of Driver Mutations during Complete Remission Associates with Shorter Survival and Contributes to the Inferior Outcomes of Elderly Patients with Acute Myeloid Leukemia. In: Annals of Hematology, Vol. 96: S31-S32

Dutta, S.; Krause, A.; Vosberg, S.; Herold, T.; Ksienzyk, B.; Quintanilla-Martinez, L.; Tizazu, B.; Chopra, M.; Graf, A.; Krebs, S.; Blum, H.; Greif, P. A.; Vetter, A.; Metzeler, K.; Rothenberg-Thurley, M.; Schneider, M. R.; Dahlhoff, M.; Spiekermann, K.; Zimber-Strobl, U.; Wolf, E.; Bohlander, S. K. (2016): The target cell of transformation is distinct from the leukemia stem cell in murine CALM/AF10 leukemia models. In: Leukemia, Vol. 30, No. 5: pp. 1166-1176

Rothenberg-Thurley, M.; Amler, S.; Goerlich, D.; Sauerland, M. C.; Schneider, S.; Konstandin, N. P.; Schaaf, S.; Batcha, A. M. Nazeer; Bräundl, K.; Ksienzyk, B.; Zellmeier, E.; Mansmann, Ulrich; Fiegl, M.; Subklewe, M.; Bohlander, S. K.; Faldum, A.; Hiddemann, W.; Spiekermann, K.; Braess, J.; Metzeler, K. H. (2016): Persistence of driver mutations during complete remission associates with shorter survival and contributes to the inferior outcomes of elderly patients with acute myeloid leukemia. In: Haematologica, Vol. 101: p. 23

Rothenberg-Thurley, M.; Amler, S.; Görlich, D.; Sauerland, M. C.; Schneider, S.; Konstandin, N. P.; Schaaf, S.; Nazeer Batcha, A. M.; Bräundl, K.; Ksienzyk, B.; Zellmaier, E.; Mansmann, Ulrich; Fiegl, M.; Subklewe, M.; Bohlander, S. K.; Faldum, A.; Hiddemann, W.; Spiekermann, K.; Braess, J.; Metzeler, K. H. (2016): Persistence of driver mutations during complete remission associates with shorter survival and contributes to the inferior outcomes of elderly patients with acute myeloid leukemia. In: Oncology Research and Treatment, Vol. 39: pp. 110-111

This list was generated on Wed Nov 13 06:49:13 2019 CET.